Hosted on MSN3d
Bispecific antibody startup Bambusa raises $90m to fund clinical trials
Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...
Bispecific Antibody Market Expands with Over 600 Clinical Trials – New Patent Analysis Report Released
Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...
The American Journal of Managed Care1d
Banner Year for Bispecifics as Therapies Advance Into the Community Setting
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
FierceBiotech6d
Boston biotech Bambusa banks $90M for next-gen bispecifics
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...
The American Journal of Managed Care5h
Geographic Barriers Impede Access to Novel Cancer Treatments
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...
Targeted Oncology2d
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...